Please select the option that best describes you:
How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?
What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?
Answer from: at Academic Institution
Both IL-17 and IL-23 agents have demonstrated excellent efficacy for psoriasis. Choosing between them often comes down to access and insurance coverage.With that being said, considerations include:
Side effect profile: The side effect profile for both IL-23 and IL-17 agents is similar, with the e...
Sign in or Register to read more
Answer from: at Academic Institution
I let patients with severe psoriasis know that both IL-23 and IL-17 blocking drugs are wonderful, both very effective and both very safe. IL-23 drugs don't require as many shots and maybe a touch safer (with less risk of candidiasis and inflammatory bowel disease as near as I can tell). IL-17 drugs ...